Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 Vancouver, British Columbia (January 08, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today provided an update on key strategic priorities for 2025 and 2026. "2024 was a pivotal year for Zymeworks, marked by the firs ...

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW209 and ZW1528 anticipated in 2026Phase 3 HERIZON-GEA-01 top-line results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) are expected 2Q-2025, with potential supplemental biologics license application (sBLA) by Jazz Pharmaceuticals later in 2025Potential regulato ...

Shares of Zymeworks Inc. (ZYME) have gained 10.1% over the past four weeks to close the last trading session at $14.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $20.44 indicates a potential upside of 41.4%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.40. While the lowest estimate of $12 indicates a 17% decline from the current ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.The Zymeworks (NASDAQ: ZYME ) story over the last two years was one of transformation and ...

VANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the company’s first-in-human Phase 1 trial (NCT06555744) to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced folate receptor-⍺ (FR⍺ ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

| --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------| | | | | | | | | | | | Q3 2024 Results | | | | | | | | | | Conference Call and Webcast October 31, 2024 | | | | | Nasdaq: ZYME \| zymeworks.com | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, an ...

Financial Data and Key Metrics - Net loss for the nine months ended September 30, 2024 was $99.2 million, compared to $104.2 million for the same period in 2023, primarily due to lower R&D and G&A expenses, and a decrease in income tax expense [17] - Revenue for the nine months ended September 30, 2024 was $45.3 million, down from $59.1 million in 2023, driven by a decrease in development support and drug supply revenue from Jazz [18] - Operating expenses decreased by 8% YoY to $160.2 million, primarily due to reduced R&D and G&A expenses [20] - Cash resources as of September 30, 2024 were $374.9 million, down from $456.3 million at the end of 2023 [24] Business Line Data and Key Metrics - ZW171 and ZW191 received FDA clearance for IND applications in August 2024, with ZW171 initiating Phase 1 trials [9] - ZW220 and ZW251 showed promising preclinical data at the ENA conference, with IND filings anticipated in 2025 [10] - Jazz Pharmaceuticals provided updates on Zani, showing a 59% 30-month overall survival rate in metastatic DEA patients in a Phase 2 study [12] - GSK contributed $2.5 million in milestone revenue, validating the company's internal platforms [13] Market Data and Key Metrics - The company has a global footprint with clinical trials for ZW171 and ZW191 active in North America, Europe, and the Asia-Pacific region [54] - ZW220 demonstrated robust activity in ovarian, endometrial, and non-small cell lung cancer models, with a single dose of 6 mg/kg showing significant antitumor efficacy [28] - ZW251 showed dose-responsive antitumor effects in hepatocellular carcinoma models, with a single 8 mg/kg dose active in 5 out of 6 cell line-derived models [38] Company Strategy and Industry Competition - The company is focused on advancing its R&D pipeline, with three 519 payload ADCs expected to enter early clinical development by the end of 2025 [42] - Zymeworks is exploring combination regimens for its ADCs to improve efficacy and tolerability, aiming to reach first-line patients [44] - The company is expanding into hematological cancers and autoimmune inflammatory diseases, leveraging its core strengths in solid tumors [62] Management Commentary on Operating Environment and Future Outlook - Management highlighted the transformative potential of the company's novel ADC designs, emphasizing the importance of target biology and tolerability [43] - The company expects to extend its cash runway into the second half of 2027, supported by anticipated regulatory milestone payments [26] - Management expressed confidence in the potential of Zani to make a significant impact in oncology, with upcoming clinical data readouts expected in 2025 [71] Other Important Information - The company completed the first $30 million of its $60 million share repurchase program, purchasing approximately 2.5 million shares at an average price of $11.79 per share [16] - A non-cash impairment charge of $17.3 million was recorded due to the discontinuation of the zanidatamab zovodotin clinical development program [22] - The company is eligible for commercial milestone payments and tiered royalties on Zani sales, with royalties ranging from 10% to 20% on Jazz's net sales and 10% to 19.5% on BeiGene's sales [27] Q&A Session Summary Question: Dose optimization for ZW171 and ZW191 Phase 1 trials - The company plans to explore multiple doses in the expansion phase to ensure a clear understanding of tolerability and efficacy [78] - Management emphasized the importance of collecting diverse patient data to optimize dosing strategies [80] Question: Combination strategies for ADCs - The company is considering combination strategies for all three ADC programs, with specific combinations tailored to the disease indication [83] - Potential combinations include VEGF inhibitors, PARP inhibitors, and PD1 inhibitors, depending on the target population [84] Question: Competitive landscape for Zani - Management expressed confidence in Zani's clinical data and its potential to outperform competitors, particularly in HER2-positive indications [89] - The company highlighted Zani's unique mechanism of action and tolerability profile as key differentiators [90] Question: Data sharing philosophy for ZW171 and ZW191 - The company plans to share clinical data only after collecting a robust dataset, likely at peer-reviewed scientific or medical meetings [95] - Early data from Phase 1 trials is not expected to be shared at the upcoming R&D Day [108] Question: Share repurchase program - The company completed the first $30 million of its $60 million share repurchase program and is evaluating market conditions before initiating the second tranche [98] - Management believes the share price remains undervalued and sees the repurchase program as a way to improve shareholder returns [100] Question: Future partnerships and collaborations - The company is open to partnerships to accelerate its R&D pipeline, particularly for its 5 by 5 portfolio and beyond [119] - Management is considering retaining more commercial rights in future collaborations compared to the Zani licensing deal [120] Question: Target selection for ADCs - The company prioritizes targets with strong antigen expression but also considers the potential for bystander activity in tumors with variable antigen expression [125] - The design of ADCs balances target recognition, internalization, and payload release to optimize efficacy and tolerability [126] Question: Expansion into autoimmune diseases - The company plans to discuss specific autoimmune programs at the R&D Day, leveraging its bispecific technology [129] - Target selection for Trispecific T-cell engagers focuses on tumor-biased expression to minimize off-target effects [130]

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.50%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four quarters, the company has surpassed c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 _____________________ ...